146 related articles for article (PubMed ID: 9873956)
1. The effect of intermittent injections of CCK-8S and the CCK-A receptor antagonist devazepide on cell proliferation in exocrine rat pancreas.
Ohlsson B; Borg K; Rehfeld JF; Ihse I; Axelson J
Int J Pancreatol; 1998 Dec; 24(3):211-8. PubMed ID: 9873956
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of cholecystokinin leads to down-regulation of the cholecystokinin-A receptor in the rat pancreas.
Ohlsson B; Borg K; Mulder H; Rehfeld JF; Axelson J; Sundler F
Scand J Gastroenterol; 2000 Jun; 35(6):612-8. PubMed ID: 10912661
[TBL] [Abstract][Full Text] [Related]
3. The method of administration of cholecystokinin determines the effects evoked in the pancreas.
Ohlsson B; Borg K; Rehfeld JF; Axelson J; Sundler F
Pancreas; 2001 Jul; 23(1):94-101. PubMed ID: 11451154
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the influence of devazepide and CCK-8S on the intact and resected rat liver.
Ohlsson B; Rehfeld JF; Axelson J
Eur Surg Res; 1998; 30(6):378-84. PubMed ID: 9838229
[TBL] [Abstract][Full Text] [Related]
5. CCK stimulates growth of both the pancreas and the liver.
Ohlsson B; Rehfeld JF; Axelson J
Int J Surg Investig; 1999; 1(1):47-54. PubMed ID: 11817337
[TBL] [Abstract][Full Text] [Related]
6. The changes in the rat parotid glands following total parenteral nutrition and pancreatico-biliary diversion are not mediated by cholecystokinin.
Axelson J; Fan BG; Ohlsson B; Rehfeld J; Ekelund M; Ihse I
Int J Pancreatol; 1996 Oct; 20(2):109-18. PubMed ID: 8968866
[TBL] [Abstract][Full Text] [Related]
7. Time-course of the pancreatic changes following long-term stimulation or inhibition of the CCK-A receptor.
Ohlsson B; Axelson J; Sternby B; Rehfeld JF; Ihse I
Int J Pancreatol; 1995 Aug; 18(1):59-66. PubMed ID: 7594771
[TBL] [Abstract][Full Text] [Related]
8. Devazepide-induced hyperplasia in the rat liver and bile ducts.
Ohlsson B; Axelson J; Rehfeld JF; Ihse I
Eur Surg Res; 1996; 28(4):299-305. PubMed ID: 8813655
[TBL] [Abstract][Full Text] [Related]
9. Total parenteral nutrition affects the tropic effect of cholecystokinin on the exocrine pancreas.
Fan BG; Axelson J; Sternby B; Rehfeld J; Ihse I; Ekelund M
Scand J Gastroenterol; 1997 Apr; 32(4):380-6. PubMed ID: 9140162
[TBL] [Abstract][Full Text] [Related]
10. Cholecystokinin does not affect the pancreatic contents of epidermal growth factor or its receptor.
Ohlsson B; Rehfeld JF; Sundler F
Pancreas; 2000 Nov; 21(4):385-91. PubMed ID: 11075993
[TBL] [Abstract][Full Text] [Related]
11. The trophic effect of cholecystokinin on the pancreas declines in rats on total parenteral nutrition.
Wu XM; Liao YW; Ji KQ; Li GF; Zang B
J Anim Physiol Anim Nutr (Berl); 2012 Apr; 96(2):214-9. PubMed ID: 21438927
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic atrophy in rats produced by the cholecystokinin-A receptor antagonist devazepide.
Nylander AG; Chen D; Ihse I; Rehfeld JF; Håkanson R
Scand J Gastroenterol; 1992 Sep; 27(9):743-7. PubMed ID: 1411279
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of cholecystokinin-A receptor mRNA in pancreas and cholecystokinin-B receptor mRNA in oxyntic mucosa after porta-caval shunting in rats.
Nylander AG; von Friesen CP; Monstein HJ; Yamada H; Chen D; Boketoft A; Håkanson R
Pharmacol Toxicol; 1997 Mar; 80(3):147-51. PubMed ID: 9101588
[TBL] [Abstract][Full Text] [Related]
14. The trophic response of rat pancreas to sulfated cholecystokinin-8 is dose- and time-dependent and not affected by vagotomy or atropine.
Nylander AG; Chen D; Ding XQ; Norlén P; Håkanson R
Pharmacol Toxicol; 1997 Mar; 80(3):142-6. PubMed ID: 9101587
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin octapeptide induces both proliferation and apoptosis in the rat pancreas.
Trulsson LM; Svanvik J; Permert J; Gasslander T
Regul Pept; 2001 Apr; 98(1-2):41-8. PubMed ID: 11179777
[TBL] [Abstract][Full Text] [Related]
16. Dose-related involvement of CCK in bombesin-induced pancreatic growth.
Liehr RM; Reidelberger RD; Rosewicz S; Bussjaeger LJ; Solomon TE
Regul Pept; 1992 Apr; 38(3):207-19. PubMed ID: 1375383
[TBL] [Abstract][Full Text] [Related]
17. Peripheral administration of cholecystokinin activates c-fos expression in the locus coeruleus/subcoeruleus nucleus, dorsal vagal complex and paraventricular nucleus via capsaicin-sensitive vagal afferents and CCK-A receptors in the rat.
Mönnikes H; Lauer G; Arnold R
Brain Res; 1997 Oct; 770(1-2):277-88. PubMed ID: 9372230
[TBL] [Abstract][Full Text] [Related]
18. High-affinity CCK-A receptors on the vagus nerve mediate CCK-stimulated pancreatic secretion in rats.
Li Y; Hao Y; Owyang C
Am J Physiol; 1997 Sep; 273(3 Pt 1):G679-85. PubMed ID: 9316472
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic profile of TS-941, a new benzodiazepine derivative cholecystokinin-receptor antagonist, in in vitro isolated rat pancreatic acini.
Tashiro M; Hirohata Y; Kihara Y; Akiyama T; Otsuki M
Pancreas; 1999 Mar; 18(2):156-64. PubMed ID: 10090413
[TBL] [Abstract][Full Text] [Related]
20. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
